• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

February 1, 2021
Company Drug/Device Medical Condition Status
COVID-19 Trials and Actions
OncoSec Medical CORVax12 COVID-19 vaccine first patients dosed in phase 1 trial
Medigen Vaccine Biologics

Dynavax
MVC-COV1901 COVID-19 vaccine first patient dosed in phase 2 trial
VBL Therapeutics VB-201 patients with severe COVID-19 first patient dosed in phase 2 trial
Other Trials and Actions
Organicell Regenerative Medicine Zofin chronic obstructive pulmonary disease IND approved by the FDA
Passage Bio PBFT02 frontotemporal dementia with granulin mutations IND approved by the FDA
Teneobio TNB-585 metastatic castrate-resistant prostate cancer IND approved by the FDA
Cardiff Oncology onvansertib metastatic pancreatic ductal adenocarcinoma IND approved by the FDA
Eucure Biopharma YH001 advanced solid tumors first patient enrolled in phase 1 trial in China
Eyepoint Pharmaceuticals EYP-1901 wet age-related macular degeneration first patient dosed in phase 1 trial
I-Mab

Morphosys
TJ210/MOR210 relapsed or refractory advanced solid tumors first patient dosed in phase 1 trial
Exelixis XL102 inoperable locally advanced or metastatic solid tumors initiation of phase 1 trial
Zymeworks ZW49 heavily pretreated HER2 positive cancers first patients enrolled in expansion cohort portion of phase 1 trial
Antios Therapeutics ATI-2173 chronic hepatitis B virus infection completion of phase 1b trial
BioInvent BI-1808 monotherapy and in combination with Keytruda (pembrolizumab) solid tumors and cutaneous T-cell lymphoma first patient enrolled in phase I/2a trial
Medicure long-term use of Aggrastat (tirofiban hydrochloride) injection aneurysmal subarachnoid hemorrhage completion of phase 1/2a trial
Ayala Pharmaceuticals AL101 notch-activated recurrent or metastatic triple negative breast cancer first patient dosed in phase 2 trial
Meissa Vaccines MV-012-968, intranasal live attenuated vaccine respiratory syncytial virus first patients dosed in phase 2 trial
Surface Ophthalmics SURF-100 (mycophenolate sodium and betamethasone sodium phosphate in Klarity vehicle) chronic dry eye disease first patient dosed in phase 2 trial
DURECT DUR-928 severe alcohol-associated hepatitis first patient dosed in phase 2b trial
SFJ Pharmaceuticals

PhaseBio
bentracimab reversal of antiplatelet effects of Brilinta (ticagrelor) first patient dosed in EU in phase 3 trial
Marinus Pharmaceuticals IV ganaxolone refractory status epilepticus first patient enrolled in phase 3 trial
Prilenia Therapeutics pridopidine early-stage Huntington’s disease first patient enrolled in Europe in phase 3 trial
Quantum Genomics firibastat treatment-resistant hypertension initiation of phase 3 trial
Telix Pharmaceuticals TLX250-CDx (89Zr-girentuximab), renal cancer diagnostic imaging agent noninvasive detection of clear-cell renal cell carcinoma first patients dosed in phase 3 trial
M6P Therapeutics four recombinant enzyme and two gene therapy programs lysosomal storage disorders Rare Pediatric Disease designations granted by the FDA
M6P Therapeutics two gene therapy programs Gaucher disease and mucolipidosis Orphan Drug designations granted by the FDA
Q BioMed Uttroside-B hepatocellular carcinoma Orphan Drug designation granted by the FDA
Veralox Therapeutics VLX-1005 heparin-induced thrombocytopenia Orphan Drug designation granted by the FDA
Junshi Biosciences toripalimab first-line treatment of mucosal melanoma Fast-Track designation granted by the FDA
PEDRA Technology PEDRA Xauron Perfusion System critical limb-threatening ischemia Breakthrough Device designation granted by the FDA
Merck KGaA

Pfizer
Bavencio (avelumab) first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are progression-free following platinum-based chemotherapy approved by the European Commission for expanded indication
Aurinia Pharmaceuticals Lupkynis (voclosporin) in combination with background immunosuppressive therapy adults with active lupus nephritis approved by the FDA
Boston Scientific Vercise Genus Deep Brain Stimulation System deep-brain stimulation in patients with Parkinson's disease approved by the FDA
Exelixis Cabometyx (cabozantinib) in combination with Opdivo (nivolumab) first-line treatment of advanced renal cell carcinoma approved by the FDA
OrthoSpin Generation 2 OrthoSpin system external fixation system for orthopedic treatments approved by the FDA
Recordati Rare Diseases Carbaglu (carglumic acid) tablets 200mg adjunctive therapy to standard of care for acute hyperammonemia due to propionic acidemia or methylmalonic acidemia in children and adults approved by the FDA for new indication
Theranica Nerivio therapeutic device acute treatment of episodic or chronic migraine in people 12 years and older approved by the FDA for expanded indication
ViiV Healthcare Cabenuva (rilpivirine and cabotegravir) HIV approved by the FDA

 

Upcoming Events

  • 06Jun

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing